Last update 21 Nov 2024
anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CD30 biAb-AATC |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
1
Clinical Trials associated with anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)Phase I Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
100 Clinical Results associated with anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)
Login to view more data
100 Translational Medicine associated with anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)
Login to view more data
100 Patents (Medical) associated with anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)
Login to view more data
100 Deals associated with anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Anaplastic Large-Cell Lymphoma | Phase 2 | US | 01 Dec 2024 | |
| CD-30 positive pleomorphic large T-cell cutaneous lymphoma | Phase 2 | US | 01 Dec 2024 | |
| CD-30 positive T-immunoblastic cutaneous lymphoma | Phase 2 | US | 01 Dec 2024 | |
| CD30-positive diffuse large B-cell lymphoma | Phase 2 | US | 01 Dec 2024 | |
| Leukemia | Phase 2 | US | 01 Dec 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | 875 | (CD30-positive patients) | cyptpscqyc(gmpwvzvnfy) = kxjluvkqhq nqcyhtewxb (wmrmqzpqps ) | - | 20 May 2012 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free